Contrary to results of smaller studies, two drugs tested in a larger trial did not improve kidney function in acute heart failure patients. Lead author and Mayo Clinic cardiologist Horng Chen, M.B., B.Ch., says, “Kidney-enhancing therapies in acute heart failure continue to elude us. In the past five years, all the major acute heart failure therapeutic clinical trials have not demonstrated beneficial effects of the therapies tested.”
In the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF) randomized 26-site trial in the U.S. and Canada, researchers analyzed data on 360 hospitalized acute heart failure patients with kidney dysfunction from September 2010 to March 2013. Compared to placebo, researchers found that neither dopamine nor nesiritide, when also used with diuretic (water pills) therapy, was better at increasing urine volume or improving levels of serum cystatin-C, an indicator of kidney function, at the end of a 72-hour treatment.
Read news release.
Journalists: Sound bites with Dr. Chen are available in the downloads.